Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MARLISSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MARLISSA.
GENCEPT 10/11-28 vs MARLISSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
MARLISSA 20 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Category C
Category C
Oral Contraceptive
Oral Contraceptive